Condition
Tislelizumab clinical trials and research
As of November 12, 2026, Find a Trial lists 9 Tislelizumab clinical trials that are recruiting, in China. By phase: Phase 2 (9). The most active sponsors are Zibo Municipal Hospital (2), Tianjin Medical University Second Hospital (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 9Clinical trials
- 1Country
Newest Tislelizumab clinical trials
All recruiting trials (9)
-
Adding tislelizumab with or without the probiotic Probio-M9 to pre-surgery chemoradiation for pMMR/MSS locally advanced rectal cancer.
This will see if adding the PD-1 drug tislelizumab, with or without the probiotic Probio-M9, to standard pre-surgery chemoradiation helps adults with pMMR/MSS locally advanced rectal cancer.
-
Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma
This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.
-
Nephron-sparing tislelizumab and nab-paclitaxel for renal pelvic cancer
This study will try combining tislelizumab and nab‑paclitaxel to shrink HER‑2–expressing renal pelvic tumors in adults eligible for ureteroscopic laser ablation.
-
Platinum-doublet chemotherapy followed by large-fraction radiotherapy with tislelizumab for advanced non-squamous NSCLC
We will try platinum-based doublet chemotherapy followed by large-fraction radiotherapy together with tislelizumab in people with stage IIIB/C–IV non-squamous non-small cell lung cancer who cannot tolerate concurrent chemoradiotherapy.
-
Neoadjuvant tislelizumab plus nab‑paclitaxel before kidney‑sparing distal ureterectomy for ureteral cancer
This will try giving people with non‑metastatic ureteral cancer two to three cycles of tislelizumab plus nab‑paclitaxel before a kidney‑sparing distal ureterectomy to see if tumor response improves and the treatment is tolerable.
-
Tislelizumab with Anlotinib and Nab-Paclitaxel before surgery for resectable NSCLC
A group of adults with stage II–III non-small cell lung cancer is given tislelizumab plus anlotinib and nab-paclitaxel before surgery to see if the treatment helps shrink tumors and is safe.
-
Concurrent chemoradiotherapy with surufatinib and tislelizumab for unresectable stage III non-small cell lung cancer
This tests whether adding surufatinib and tislelizumab to standard concurrent chemoradiotherapy, followed by continuing both drugs as consolidation, helps people with unresectable stage III non-small cell lung cancer.
-
Tislelizumab with platinum-doublet chemotherapy followed by hypofractionated radiotherapy for stage IIIB/C–IV non-squamous NSCLC
This trial tests whether adding Tislelizumab to platinum-doublet chemotherapy followed by hypofractionated radiotherapy can help people with stage IIIB/C–IV non‑squamous non‑small cell lung cancer who have not had prior systemic therapy.
-
Combining Lenvatinib, Tislelizumab, and TACE for Liver Cancer Treatment
This study is testing a new combination treatment for liver cancer to see if it can help patients at high risk of their cancer coming back after surgery.
Related topics
Quick answers
How many Tislelizumab clinical trials are recruiting right now?
9, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 9. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.